# DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

> **NCT03877224** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 504 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** Dapagliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03877224
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-07-09
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2021-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03877224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03877224, "DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03877224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*